(MedPage Today) — BERLIN — Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be safe in prostate cancer…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118033
Author :
Publish date : 2025-10-20 16:30:00
Copyright for syndicated content belongs to the linked Source.
